The Week

Twist Bioscience (TWST.US) rose 31.26% this week to close at $166.99, while the S&P 500 slipped 0.08%, leaving the stock roughly 31.34 percentage points ahead of the benchmark. The week was a steady climb rather than a choppy range. It opened Monday at $121.92, pressed higher each session, and finished Friday at $166.99, just below the weekly high of $167.05. Daily average volume came in around 2.39m shares, about 61.78% above its longer-run median.

Key Events

The narrative took shape mid-week. On Tuesday evening, a broader industry piece about the 2026 divide between AI fortunes and consumer squeezes entered the tape, framing the risk-on tone. Wednesday brought the headline that mattered: Twist reached a partnership with Eli Lilly’s TuneLab, aimed at closing the gap between AI models and lab data. The shares moved higher that day and again on Thursday as the deal made the rounds in media coverage. By Friday, the story had expanded to include Lilly and Anthropic deepening AI-driven drug discovery, pushing TWST sharply higher on heavy volume. The same day BWS Financial reiterated a sell rating with a $45 price target, so the tape was not without pushback as the stock climbed.

Analyst Ratings

Coverage stands at 13 firms: 7 rate it buy, 2 overweight, 3 hold, and 1 sell. The consensus rating is buy, but the consensus target of $109.58 sits roughly 34.38% below the current price, a sign the rally has outrun the average target. The spread between targets is unusually wide: the high is $160 and the low is $36, against a spot price of $166.99. Within the biotech industry, TWST ranks 84th out of 501 for analyst sentiment, which places it in the upper-middle tier rather than the very front of the pack.

The Week Ahead

The macro calendar is the main focus. Tuesday brings the Richmond Fed composite index, Wednesday brings EIA crude and Cushing inventory data, and Thursday brings initial jobless claims, the current account balance, new home sales, and EIA natural gas inventories. None of these are company-specific, but with rates and risk appetite dominating, they could shape the tape into the second half of the week. There is no earnings release on the calendar for TWST, so the next catalyst to watch is whether more detail surfaces around the Lilly TuneLab partnership following this week’s spike.

In Short

This week TWST ran on a single narrative: a partnership with Lilly’s TuneLab, with AI drug discovery as the tailwind. The stock gained more than 30% while the benchmark was essentially flat. The tension is between price and consensus opinion: most brokers rate it buy, yet the average target is far below spot, and target dispersion is unusually wide. The latest session’s order flow also showed small-lot buyers leaning in while large-lot money was a mild net seller. The next test is whether the macro calendar and any follow-up on the TuneLab deal justify the move.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.